Clinical trial design for non-muscle-invasive bladder cancer

被引：3
|
作者：
Tan, Wei Shen [1 ,2 ]
Hall, Emma [3 ]
Kamat, Ashish M. [1 ]
Kelly, John D. [2 ,4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[2] UCL, Div Surg & Intervent Sci, London, England
[3] Inst Canc Res, Clin Trials & Stat Unit, London, England
[4] Univ Coll London Hosp, Dept Urol, London, England
来源：
NATURE REVIEWS UROLOGY | 2023年 / 20卷 / 10期
关键词：
D O I：
10.1038/s41585-023-00789-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The heterogeneous nature of non-muscle-invasive bladder cancer is a challenge for clinical trial design. Careful consideration in clinical trial design, choice of end points and adequate patient characterization is important when evaluating new therapies.
引用
收藏
页码：575 / 576
页数：2
相关论文
共 50 条
  • [31] Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer
    Campi, Riccardo
    Seisen, Thomas
    Roupret, Morgan
    EUROPEAN UROLOGY FOCUS, 2018, 4 (04): : 472 - 480
  • [32] Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
    Youssef, Ramy F.
    Lotan, Yair
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 369 - 381
  • [33] Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer
    Roldan, Fiorella L.
    Ingelmo-Torres, Mercedes
    Mercader, Claudia
    Figueras, Marcel
    Padulles, Bernat
    Duran, Maria Angeles
    Carrasco, Josep L.
    Ribal, Maria Jose
    Franco, Agustin
    Izquierdo, Laura
    Alcaraz, Antonio
    Mengual, Lourdes
    BJU INTERNATIONAL, 2025,
  • [34] Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
    Kamat, Ashish M.
    Sylvester, Richard J.
    Bohle, Andreas
    Palou, Joan
    Lamm, Donald L.
    Brausi, Maurizio
    Soloway, Mark
    Persad, Raj
    Buckley, Roger
    Colombel, Marc
    Witjes, J. Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1935 - +
  • [35] Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial?
    del Rey, Javier
    Placer, Jose
    Vallmanya, Felip
    Pujol, Nuria
    Prat, Esther
    Miro, Rosa
    Gelabert, Antoni
    BJU INTERNATIONAL, 2010, 106 (01) : 49 - 52
  • [36] Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
    Zhu, Huier
    Chen, Hui
    Wang, Jizhong
    Zhou, Ling
    Liu, Shaoyan
    ONCOTARGETS AND THERAPY, 2019, 12 : 3441 - 3457
  • [37] Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression A Randomized Clinical Trial
    Bryan, Richard T.
    Pirrie, Sarah J.
    Abbotts, Ben
    Maycock, Shanna
    During, Vinnie
    Lewis, Carolyn
    Grant, Margaret
    Bird, Deborah
    Devall, Adam J.
    Wallace, D. Michael A.
    James, Nicholas D.
    Billingham, Lucinda J.
    Zeegers, Maurice P.
    Cheng, K. K.
    JAMA NETWORK OPEN, 2023, 6 (10) : E2337494
  • [38] Dynamic expression changes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer
    Zhao, Yu-gang
    Shi, Bing-yi
    Qian, Ye-yong
    Bai, Hong-wei
    Xiao, Li
    He, Xiu-yun
    TUMORI JOURNAL, 2014, 100 (06): : E273 - E281
  • [39] Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer
    Jooae Choe
    Marta Braschi-Amirfarzan
    Sree Harsha Tirumani
    Atul B. Shinagare
    Kyung Won Kim
    Nikhil H. Ramaiya
    Katherine M. Krajewski
    Abdominal Radiology, 2017, 42 : 2710 - 2724
  • [40] Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA
    Barocas, Daniel A.
    Globe, Denise R.
    Colayco, Danielle C.
    Onyenwenyi, Ahunna
    Bruno, Amanda S.
    Bramley, Thomas J.
    Spear, Rachel J.
    ADVANCES IN UROLOGY, 2012, 2012
12345